CBD & Cannabis Statistics

At CannaHealth, our team works hard to find the latest CBD and medical cannabis research and present their findings to readers in a clear and concise way. In addition to publishing summaries of the newest, interesting, and most important research, we wanted to create a page where you can easily find the facts related to your specific inquiry.

How to Use the CBD Statistics and Cannabis Page:

We’ve divided the results by ailment or category. Just use the Table of Contents below to find the ailment or area of interest you are researching. For each, we’ve included the source, and the year the data was published. Study findings are listed in chronological order from top to bottom under each topic area.

For information that we’ve published elsewhere on the site, you’ll find a link to easily access that content.

This page is being update all the time — consider subscribing to our weekly medical cannabis and CBD newsletter to stay on top of news and important research being done on the marijuana industry.


Of 21 patients on opioid pain medications for post-traumatic concussions, 38% of patients decreased or discontinued their pain medications when treated with medical cannabis. (Neurology, 2019)

In states where marijuana is available through medical channels, a modestly lower rate of opioid and high-risk opioid prescribing was observed. Medical marijuana legalization was associated with a lower odds of any opioid use: OR = 0.95 (0.94–0.96), chronic opioid use: OR = 0.93 (0.91–0.95), and high-risk opioid use: OR = 0.96 (0.94–0.98). (Journal of Internal Medicine, 2019)

Thirty-two (32%) percent of people who try tobacco become dependent, whereas 15% who try alcohol and only 9% who try marijuana become dependent. (Berkeley Journal of Criminal Law, 2018)

Owing to substantial methodological issues, previous epidemiological and clinical studies examining marijuana smoking on the risk of tobacco-sensitive lung diseases (e.g., lung cancer and chronic obstructive pulmonary disease [COPD]) have not produced consistent results. (Canadian Medical Association Journal, 2018)

There is emerging scientific evidence indicating that marijuana can serve as a pathway away from dependency of more dangerous substances, including prescription drugs, heroin, and alcohol. (Berkeley Journal of Criminal Law, 2018)

Administration of a therapeutic dose of CBD (750 mg) showed significantly low abuse potential in a highly sensitive population of polydrug users. (Epilepsy Behavior, 2018)

States permitting medical marijuana dispensaries experience a relative decrease in opioid addictions and opioid overdose deaths (RAND BING Center for Health Economics, 2015)

Cigarette smokers who used CBD smoked approximately 40% fewer cigarettes when using CBD. (Addictive Behaviors, 2013)

Unlike other addictions, cannabis dependence of mild to moderate severity is not associated with dopamine release alterations in the brain. However, earlier or longer duration of use is related to lower dopamine release. These observations suggest a more harmful effect of using marijuana during adolescence. (Biological Psychiatry, 2012)

Aging Effects

In one small study of ten women with severe dementia, an oral cannabis extract with THC/CBD, in higher doses than in other studies, was well tolerated and greatly improved behavior problems, rigidity, and daily care. (Medical Cannabis and Cannabinoids, 2019)

64% of seniors rated their quality of life as “good” after using CBD, up from 31.1% prior to using CBD. (Remedy Review, 2018) 61.1% of seniors who tried CBD reported reduced pain. (Remedy Review, 2018)

45.6% of seniors who used CBD said it improved their sleep quality. (Remedy Review, 2018)

7.8% of seniors reported CBD improved their cognitive function. (Remedy Review, 2018)

5.6% of seniors who tried CBD reported decreased blood pressure. (Remedy Review, 2018)

Overall, 28.9% of CBD users over age 54 claimed it was “extremely effective” at treating symptoms.(Remedy Review, 2018)

Findings from a small study suggest that, when carefully matched on baseline variables and not differing in IQ or alcohol use, young, near-daily cannabis users do not differ from non-using control subjects in prospective memory performance. (Frontiers in Psychology, 2018)

Patients with dementia-related agitation and appetite loss who were treated with dronabinol – a cannabinoid – (average dosage =7.03 mg/d) experienced significant reductions in all aspects of agitation, including aberrant vocalization, motor agitation, aggressiveness, and treatment resistance (p <.0001), but no significant improvements in appetite. (Am J Geriatr Psychiatry, 2014)


Among people using benzodiazepines (commonly prescribed to reduce anxiety) who took CBD, 45.2% were able to stop using benzodiazepines. (Cannabis and Cannabinoid Research, 2019)

THC or CBD given in addition to other pharmacotherapies and psychotherapy improved specific symptoms of some disorders (e.g. in dementia, cannabis and opioid dependence, schizophrenia, general social anxiety, post-traumatic stress disorder, anorexia nervosa, attention-deficit/hyperactivity disorder, and Tourette`s disorder). (European Archives of Psychiatry and Clinical Neuroscience, 2019)

High-dose oral CBD (150–600 mg/d) may exert a therapeutic effect for social anxiety disorder, insomnia and epilepsy, but also that it may cause mental sedation (Cannahealth, 2019)

30% of people over age 54 reported CBD reduced their anxiety. (Remedy Review, 2018)

Existing preclinical evidence strongly supports CBD as a treatment for generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive–compulsive disorder, and post-traumatic stress disorder when administered acutely; however, few studies have investigated chronic CBD dosing. (Neurotherapeutics, 2015)


61% of caregivers for children diagnosed with autism spectrum disorder (ASD) reported patients’ symptoms were “much improved” or “very much improved” after using CBD. (Journal of Autism and Developmental Disorders, 2018)

80% of parents whose ASD-positive children took CBD reported a decrease in problematic behavior that had been unaffected by conventional drugs, and 62% reported “significant improvement.” (Leafly, 2018)

50% of parents of children with ASD reported improved communication after taking CBD. (Leafly, 2018)

40% of ASD-positive children who used CBD showed significant decreases in anxiety. (Leafly, 2018)

Breastfeeding, Human Lactation and Pregnancy

Maternal exposure to marijuana during pregnancy could lead to dysregulation of the immune system of the developing fetus. This could potentially lead to immune deficiencies, infection, and even cancer later in life. (Cellular and Molecular Life Sciences, 2019)

A recent investigation of substance use among pregnant women suggests that cannabis use alone is not associated with a significantly increased risk of adverse events. (Current Drug Research Reviews, 2019)

In a 2019 position statement issued by the Journal of Rheumatology, pregnant and breastfeeding women are contraindicated for treatment with cannabis. (Journal of Rheumatology, 2019)

Though there is potential for cannabis to interfere with neurodevelopment, no human data have been identified that show meaningful differences between children exposed during pregnancy to cannabis and those not exposed. (Current Drug Research Reviews, 2019)

The impact of cannabis use among pregnant women and breastfeeding mothers is difficult to determine because those who use it often use other drugs, so it is challenging to determine causational factors. (Current Drug Research Reviews, 2019)

The American Academy of Pediatrics (AAP) recommends women who are pregnant or breastfeeding avoid marijuana use based on the available evidence. No amount of marijuana has been proven safe to use during pregnancy or while breastfeeding. (American Academy of Pediatrics, 2018)

Legalization of marijuana may give the false impression that marijuana is safe. Given ethical concerns, there are no randomized controlled trials on the effect of marijuana use by pregnant and lactating women, and the available longitudinal studies must be viewed with caution. However, highlighted in the available data are concerns regarding both short-term growth and long-term neurodevelopmental and behavioral consequences of prenatal exposure to marijuana. (The American Academy of Pediatrics, 2018)

The Centers for Disease Control and Prevention (CDC) recommend that, although more research is needed to better understand how marijuana may affect women and their fetuses during pregnancy, it is recommended that pregnant women do not use marijuana. (Centers for Disease Control and Prevention, 2018)

Chemicals from marijuana can be passed to your baby through breast milk when breastfeeding. THC is stored in fat and is slowly released over time, meaning your baby could still be exposed even after you stop using marijuana. (Centers for Disease Control and Prevention, 2018)

Research on the effects of marijuana exposure to a baby through breastfeeding are limited and conflicting. To limit potential risk to the infant, breastfeeding mothers should avoid marijuana use. (Centers for Disease Control and Prevention, 2018)

Breastfeeding has numerous valuable health benefits for the mother and the infant, particularly the preterm infant. Limited data reveal that THC does transfer into human milk, and there is no evidence for the safety or harm of marijuana use during lactation. (The American Academy of Pediatrics, 2018)

Between 2002 and 2016, past-month marijuana use among pregnant women increased from 2.85% to 4.98%. (JAMA Pediatrics, 2018)

In a 2018 survey, prevalence rates of marijuana use during pregnancy were as high as 8.5% in women aged 18 to 25 years. (JAMA Pediatrics, 2018)

Recent systematic reviews suggest that use of marijuana during pregnancy may be associated with adverse outcomes, including stillbirth, fetal growth restriction, and preterm birth. (Obstetric Gynecology, 2018)

In a 2018 study, no differences in gestational age or birthweight were observed between babies born to mothers who smoked marijuana during pregnancy and those who did not. After birth, mothers who used marijuana during pregnancy were more likely to smoke cigarettes, experience postpartum depressive symptoms, and breastfeed for less than 8 weeks. (Drug and Alcohol Dependence, 2018)

Using marijuana to counter nausea during the first trimester of pregnancy is seen as a common pattern of consumption. (Annals of Internal Medicine, 2017)

A review of data on cannabis use during pregnancy concluded that THC crosses the placenta and fetal exposure to cannabis may cause subtle changes in cognition and psychological health. (American Journal Obstetric Gynecology, 2015)

A 2014 epidemiologic study of 4735 pregnant women in Hawaii found that self-reported prenatal marijuana use was more prevalent among those with (3.7%) vs without (2.3%) self-reported severe nausea during pregnancy. (Hawaii J Med Public Health, 2014)


Although the use of cannabinoids such as CBD has been documented, clinical trials on their application as anti-cancer drugs are still ongoing. There is hope that cannabinoids are successfully translated into oncological care with further research. (Frontiers in Pharmacology, 2019)

Cannabinoids were shown to be of potential use for therapeutic approaches of glioblastoma. (Cell Adhesion & Migration, 2017)

CBD induced the death of breast cancer cells in a 2006 study. Researchers concluded that further investigation is needed to benefit from CBD’s potential to inhibit the growth of tumors. (Journal of Pharmacology and Experimental Therapeutics, 2006)

Cognitive Effects

In a study of adults with attention deficit hyperactivity disorder (ADHD), a positive effect was found on the measurements of hyperactivity and impulsivity, but not on the measurement of attention and cognitive performance. (Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019)

Marijuana that contains equal ratios of CBD and THC appears to impair driving ability to the same extent that THC-dominant cannabis does. In one small clinical trial, CBD actually exacerbated THC-induced impairment while driving. (Psychopharmacology, 2019)

Cannabinoid agents work through multiple pathways in the brain, such as serotonin, to alter PTSD symptomology. More clinical trials are needed to explore the pharmacological development of cannabinoids for the treatment of PTSD. (Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019)


In a recent observational study, no association was found between regular cannabis use and severity of anxious or depressive symptoms among participants. (Journal of Affective Disorders, 2019)

In recent animal model studies, findings suggests that CBD promotes a rapid and sustained antidepressant effect. More clinical trials are needed in humans to explore the effects of CBD as an antidepressant. (Journal of Chemical Neuroanatomy, 2019)

High CBD (>9.5%) Low THC (<5.5%) cannabis was associated with the largest perceived changes in feelings of depression in a self-reported study. (Journal of Affective Disorders, 2018)


Cannabidiol (CBD) may have beneficial effects on the quality of life of persons with treatment-resistant epilepsy and those effects are not dependent on improvements in seizure control. (Epilepsy & Behavior, 2019)

In a recent review of prior and current clinical trials, it was concluded that available results demonstrate the efficacy of CBD to treat epilepsy in combination with anti-epileptic drugs (AEDs). Further research is needed to understand drug-drug interactions. (Molecules, 2019)

Two large clinical trials have demonstrated improvements in seizure reduction in children taking CBD as compared to children who were not. While there is little data regarding CBD and other related products in the treatment of adults with treatment resistant seizures, one randomized controlled clinical trial is underway. (Recent Advances in Cannabinoid Research [book], 2019)

Patients taking 20mg of CBD reported 42% decrease in seizures, while patients taking 10mg reported 37% reduction in seizures with fewer side effects. (New England Journal of Medicine, 2018)

Children age 2 – 18 diagnosed with Dravet syndrome (a drug resistant form of epilepsy involving convulsive seizures and high mortality) experienced a 22.8% reduction in seizures when using CBD. (New England Journal of Medicine, 2017)

In a small study, CBD treatment for intractable epilepsy yielded a significant positive effect on seizure load. Most of the children (66/74, 89%) reported reduction in seizure frequency: 13 (18%) reported 75–100% reduction, 25 (34%) reported 50–75% reduction, 9 (12%) reported 25–50% reduction, and 19 (26%) reported <25% reduction. (Seizure – European Journal of Epilepsy, 2016)

2% of epileptics using CBD reported a total cessation of seizures. (Scientific American, 2016)

People aged 1 – 30 diagnosed with severe, treatment-resistant epilepsy reported a 36.5% median reduction in monthly motor seizures when using CBD. (The Lancet, 2015)

Among parents of children taking CBD to treat severe epilepsy, 11% reported a complete cessation of seizures, 42% reported an 80% or more reduction in seizure frequency, and 32% reported a 25% – 60% reduction in frequency. (Epilepsy Behavior, 2013)


THC can reduce inflammation of the eye associated with glaucoma, however to be an effective treatment, a person would have to dose multiple times a day, around the clock, which would impair their ability to perform everyday tasks. (American Academy of Ophthalmology, 2019)

IBD & Chohn’s Disease

Cannabis use may mitigate several complications of Crohn’s disease possibly due to the effect of cannabis in the endocannabinoid system. (Digestive Diseases and Sciences, 2019)

Cannabinoids are well-established modulators of gut motility and visceral pain and have demonstrated anti-inflammatory properties. Clinical trials suggest that there may be a therapeutic role for cannabinoid therapy in the treatment of inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), nausea and vomiting, and GI motility disorders. However, neither has been compared to standard therapy in IBD. (Current Gastroenterology Reports, 2019)

Among adolescent patients (ages 13-23) with inflammatory bowel disease (IBD), 53% reported using marijuana most commonly for relief of physical pain. Users of marijuana were 10.7 times more likely to perceive low risk of harm with regular use of marijuana and perceived use of marijuana as beneficial for their condition. (Journal of Pediatrics, 2018)


Students with younger age at first use of marijuana had significantly higher odds of current marijuana use, a higher frequency of consumption, and were more likely to drive after use of marijuana. Effective enforcement of age restriction laws in combination with other prevention efforts may be beneficial in delaying the age of onset of marijuana until late adolescence and early adulthood. (Addictive Behaviors, 2019)

In a study aiming to understand why women typically demonstrate a more conservative stance on the issue of marijuana legalization than men, researchers found that the greater religiosity of women plays a role. The greater tendency of men to use marijuana as compared to women was found to be a major factor in this gender gap. (Social Science Quarterly, 2019)

Previous studies have demonstrated that states in the U.S. that have legalized marijuana have seen an increase in unintentional pediatric exposures in the years following legalization. Measures to mitigate or prevent toxicity, such as child-resistant packaging of marijuana products, have been taken by many states. (Clinical Pediatrics, 2019)

A conversation on insurance coverage of cannabis and cannabis-related products is relevant to the potential decriminalization of the substance. In circumstances for which cannabis or related products may be helpful, insurance companies are uniquely able to promote the safe and rational use of the plant by aligning coverage with evidence-based research that supports its use. (American Journal of Bioethics, 2019)

About six-in-ten Americans (62%) say that marijuana should be legalized. (Pew Research Center, 2018)

Self-medication with marijuana was 21.22 percentage points higher among those people living in states with medical marijuana laws. (Drug and Alcohol Dependence, 2018)

The past fifty years of drug policy in the U.S. have demonstrated that we cannot criminalize people out of using substances. If we do, we are left with widespread consumption through an unregulated and uncontrolled market, making consumption and use more dangerous to the consumer. (Berkeley Journal of Criminal Law, 2018)

The Congressional Research Service projects that replacing criminalization with a system of taxation and regulation would yield a potential $6.8 billion in excise taxes. (Berkeley Journal of Criminal Law, 2018)

In 2017, for the first time, a majority of Republicans expressed support for legalizing marijuana; the current 51% demonstrated an increase of nine percentage points from 2016. (Gallup Poll: Social Series, 2017)

Americans continue to warm to legalizing marijuana, with 64% now saying its use should be made legal. This is the highest level of public support Gallup has found for the proposal in nearly a half-century of measurement. (Gallup Poll: Social Series, 2017)

A recent meta-analysis of 11 studies concluded that legalization of medical marijuana up until 2014 did not lead to significant increases in adolescent marijuana use prevalence. (Society for the Study of Addiction, 2017)

Colorado’s legalization of recreational cannabis sales and use resulted in a 0.7 deaths per month reduction in opioid-related deaths. This reduction represents a reversal of the upward trend in opioid-related deaths in Colorado, suggesting that legalization of cannabis is associated with short-term reductions in opioid-related deaths. (American Journal of Public Health, 2017)

In 2016, 57% percent of the population supported the legalization of marijuana, an increase from 32% of the population a decade ago. (Pew Research Center, 2016)


100% of patients who experienced headaches and migraines reported a decrease in pain and discomfort when using CBD. (Care by Design, 2015)

Multiple Sclerosis (MS)

In a 2018 survey about cannabis treatment in migraine and headache, researchers found that chronic pain was the most common reason for cannabis use, consistent with most other registries. Hybrid strains were preferred in ID Migraine™, headache, and most pain groups, with “OG Shark”, a high THC (Δ9-tetrahydrocannabinol)/THCA (tetrahydrocannabinolic acid), low CBD (cannabidiol)/CBDA (cannabidiolic acid), strain. (The Journal of Headache and Pain, 2018)

In patients with refractory multiple sclerosis (MS), after 12 weeks of treatment with nabiximols, an oral mucosal spray of a formulated extract of Cannabis that contains THC and CBD, patients experienced a statistically significant reduction in spasticity based on NRS score (P = .0002). (Eur J Neurology, 2011)

Pain Management

Women with endometriosis, a condition where endometrial tissue is found outside the uterus causing severe pelvic pain, often turn to self-management strategies to deal with the symptoms. In a large sample of 480 women, cannabis, heat, hemp/CBD oil, and dietary changes were the most highly rated in terms of self-reported effectiveness in pain reduction. (BMC Complementary and Alternative Medicine, 2019)

Two recent case studies of men who had been in motor vehicle accidents and sustained spinal injuries demonstrate how CBD use may provide substantial pain relief – even more so than from the widely prescribed opioid and non-opioid analgesics. (Open Science Journal of Psychology, 2019)

The routes of administration that produced optimal benefit for post-traumatic concussion patients were 20:1 (THC:CBD) oral tincture and 20:1 vapor inhalation pen for acute pain. (Neurology, 2019)

About 81% of U.S. adults believe marijuana has at least 1 benefit, whereas 17% believe it has no benefit. The most common benefit cited was pain management (66%), followed by treatment of diseases, such as epilepsy and multiple sclerosis (48%), and relief from anxiety, stress, and depression (47%). (Annals of Internal Medicine, 2018)

97% of respondents reported using cannabis primarily for treating chronic pain and reported and average pain improvement on a 0–10 pain scale of 5.0, which translates to a 64% relative decrease in average pain. Half of all 100 respondents also noted relief from stress/anxiety, and nearly half (45%) reported relief from insomnia (Hawaii Journal of Medicine and Public Health, 2014)

Fifty-seven percent of patients with chronic pain given vaporized marijuana (average 8 to 12 puffs per visit) over 3 sessions reported pain reduction in a low-dose group and 61% of individuals reported pain reduction in a high-dose group. (Journal of Pain, 2013)

THC:CBD extract, a nonopioid analgesic containing CBD and THC extract, assists in relieving pain in patients with advanced cancer. Twice as many patients taking THC:CBD showed a reduction of more than 30% from baseline pain scores, demonstrating that THC:CBD extract is effective for relieving pain in patients with advanced cancer pain that is not fully relieved by strong opioids. (Journal of Pain and Symptom Management, 2010)

Pre-clinical and clinical studies have demonstrated that cannabis-based drugs have therapeutic potential in inflammatory diseases, including rheumatoid arthritis (RA) and multiple sclerosis. (Arthritis Research and Therapy, 2008)

Nabilone, dronabinol, and IM levonantradol (all cannabinoids) were found to be more effective in preventing vomiting and nausea among patients undergoing chemotherapy as compared with prochlorperazine, metoclopramide, chlorpromazine, thiethylperazine, haloperidol, domperidone, or alizapride (antiemetic medications). 38% to 90% of patients going through chemotherapy prefer medical marijuana over the traditional anti-vomiting and anti-nausea medications. (British Medical Journal, 2001)

Parkinson’s Diseases

In three studies, one of which was a randomized controlled trial, CBD was well-tolerated in individuals with Parkinson’s Disease. Significant therapeutic effects were seen in non-motor symptoms of individuals with the disease (i.e. psychosis; rapid eye movement). Large clinical trials are needed in order to test the long-term effectiveness and safety of CBD in the treatment of Parkinson’s Disease. (European Archives of Psychiatry and Clinical Neuroscience, 2019)

Some preclinical studies and a small number of human trials indicate possible neuroprotective and therapeutic effects of cannabidiol (CBD) in patients with Parkinson’s Disease. (European Archives of Psychiatry and Clinical Neuroscience, 2019)

Post-Traumatic Stress Disorder (PTSD)

MAPS has completed the first-ever clinical trial of smoked marijuana for symptoms of post-traumatic stress disorder (PTSD) in veterans of war. Results are due to be published in June of 2019. (Multidisciplinary Association for Psychedelic Studies, 2019)

Patients in a psychiatric ward experienced a decrease in PTSD symptom severity when given CBD. Overall, the sample’s symptom severity decreased 28% after eight weeks of consecutive treatment with CBD. The administration of CBD in addition to routine psychiatric care was associated with PTSD symptom reduction. (Journal of Alternative and Complementary Medicine, 2019)

Currently, there is a trial investigating whether the addition of CBD to exposure therapy is effective in reducing phobic symptoms for patients with social phobia or panic disorder with agoraphobia. (BMC Psychiatry, 2019)

Currently, 24 states have approved medical cannabis specifically for the treatment of PTSD. These states include: Arizona, Arkansas, Colorado, Connecticut, Delaware, Florida, Hawaii, Illinois, Maine, Michigan, Minnesota, Montana, Nevada, New Hampshire, New Mexico, New York, North Dakota, Ohio, Oregon, Pennsylvania, Rhode Island, Vermont, Washington, and West Virginia. (ECHO Connection, 2017)

The use of nabilone (maximum dose: 3 mg/d), a synthetic cannabinoid, in military personnel with PTSD resulted in a significant (p =0.03) reduction in nightmares as measured by the CAPS recurrent distressing dream tool. (Psychoneuroendocrinology, 2015)

Data from 4 small studies suggested that cannabinoid use was associated with global improvements in PTSD symptoms or amelioration of specific PTSD symptoms such as insomnia and nightmares. (American Journal of Health-System Pharmacy, 2015)

PTSD patients saw a 75% reduction in PTSD symptoms when they were using cannabis compared to when they were not. (Journal of Psychoactive Drugs, 2014)


Experts in the field of Psychiatry are interested in CBD as treatment for many psychiatric disorders, however, the evidence is still too scarce to include cannabidiol as part of a treatment plan. Large, randomized control trials are needed in order for the substance to be seriously considered in this field. (The World Journal of Biological Psychiatry, 2017)

In patients with schizophrenia or schizophreniform disorder taking CBD for two to four weeks, there was a significant reduction of psychotic symptoms with no significant differences observed between CBD as treatment or an antipsychotic drug (amisulpride); however, CBD induced significantly less side effects (Brazilian Journal of Medical and Biological Research, 2006).

Skin & Inflammation-related skin conditions

The topical administration of CBD ointment, without any THC, can improve the quality of life in patients with some skin disorders – particularly those disorders where inflammation is an issue. (La Clinica Terapeutica, 2019)


THC can improve sleep in people using cannabis, and strains of cannabis with higher THC contents can result in decreased sleepiness the following day. (Sleep, 2019)

In one large survey of 571 participants, 67% reported using cannabis for insomnia with the remaining reporting sleep disturbances related to pain (16%), anxiety (11%) or pain and anxiety (6%). (Sleep, 2019)

Out of 72 adults presenting with primary concerns of anxiety or poor sleep, 79.2% experienced a decrease in anxiety scores within the first month of taking CBD in capsule form, which remained decreased during the study duration. Out of that sample, 66.7% of patients experienced improved sleep scores within the first month, but these scores fluctuated over time. (The Permanente Journal, 2019)

Recent use of cannabis at age 18 years was associated with poor sleep quality, suggesting a potential relationship between specific facets of cannabis use that are related to poor sleep in adolescents. (Psychology of Addictive Behaviors, 2019)

Medical cannabis (MC) treatment provided the greatest improvement to sleep (80%), headache (77%), and mood (77%) among post-traumatic concussion patients. (Neurology, 2019)

Nighttime administration of THC reduced the frequency and intensity of nightmares in 72% of the 47 patients studied in a clinical trial. (CNS Neuroscience and Therapeutics, 2009)


In a two-year, self-report study, patients recorded an average symptom improvement of 3.5 on an 11-point scale across a total of 27 symptom categories. Among those participants, dried flower was the most commonly used product and was associated with greater symptom relief than other types of products cannabis products.  Higher THC levels were independently associated with greater symptom relief and prevalence of positive and negative side effects. (Scientific Reports, 2019)

A recent study found that, to understand the link between cannabis potency and health outcomes, the most important thing to study in the future is the various potency levels across separate methods of administration. (Behavior Research and Therapy, 2019)

High CBD (>9.5%) Low THC (<5.5%) cannabis was associated with the largest perceived changes in feelings of depression in a self-reported study. (Journal of Affective Disorders, 2018)

High CBD (>11%) High THC (>26.5%) produced the largest perceived changes in stress in a self-reported study. (Journal of Affective Disorders, 2018)

In one small study, a THC+CBD strain was associated with lower levels of cannabis craving, subjective intoxication, and circulating cytokines among participants immediately after use. (Cannabis and Cannabinoid Research, 2018)

In one study, nearly 70% of the CBD products researchers purchased online were mislabeled. Underlabeling of products was less concerning as CBD appears to have no serious adverse consequences at high does, however, underlabeling of THC content in products may be sufficient to produce issues, especially among children. (JAMA, 2017)


30% of people over age 54 reported lower stress levels a result of using CBD. (Remedy Review, 2018)

High CBD (>11%) High THC (>26.5%) produced the largest perceived changes in stress in a self-reported study. (Journal of Affective Disorders, 2018)

Weight & Metabolic Conditions

The association between metabolic syndrome and frequent cannabis use was significant for men (AOR = 0.49, 95% CI = 0.31-0.78), but not for women (AOR = 0.68, 95% CI = 0.37–1.24). Frequent cannabis use was associated with lower odds of abdominal obesity, hypertension and elevated triglyceride levels in men only. (Drug and Alcohol Dependence, 2019)